Related Experiment Video
Updated: Feb 12, 2026

Flow Cytometric Analysis of Particle-bound Bet v 1 Allergen in PM10
Published on: November 19, 2016
BET-ting on Nrf2: How Nrf2 Signaling can Influence the Therapeutic Activities of BET Protein Inhibitors
Nirmalya Chatterjee1, Dirk Bohmann2
1Department of Genetics, Harvard Medical School, Boston, MA 02115, USA.
Abstract:
BET proteins such as Brd3 and Brd4 are chromatin-associated factors, which control gene expression programs that promote inflammation and cancer. The Nrf2 transcription factor is a master regulator of genes that protect the organism against xenobiotic attack and oxidative stress. Nrf2 has demonstrated anti-inflammatory activity and can support cancer cell malignancy. This review describes the discovery, mechanism and biomedical implications of the regulatory interplay between Nrf2 and BET proteins. Both Nrf2 and BET proteins are established drug targets. Small molecules that either activate or suppress these proteins are currently tested in clinical trials. The crosstalk between Nrf2 and BET proteins may have important, and until now overlooked, implications for the therapeutic effects of these drugs. Based on the information covered in this review, it should be possible to design combinatorial treatment strategies for cancer and inflammatory diseases, which may improve the efficacy of targeting a Nrf2 or BET proteins individually.
Insights
The interplay between BET proteins and the Nrf2 pathway influences inflammation and cancer. Understanding this crosstalk can lead to improved combination therapies for these diseases.
Area of Science:
- Molecular Biology
- Cancer Biology
- Immunology
Background:
- BET proteins (Brd3, Brd4) regulate gene expression in inflammation and cancer.
- Nrf2 is a key regulator of cellular defense against oxidative stress and xenobiotics.
- Nrf2 exhibits both anti-inflammatory properties and roles in cancer progression.
Purpose of the Study:
- To review the discovery and mechanisms of the regulatory interplay between Nrf2 and BET proteins.
- To discuss the biomedical implications of this Nrf2-BET protein interaction.
- To explore potential therapeutic strategies based on this crosstalk.
Main Methods:
- Literature review of studies on Nrf2 and BET protein interactions.
- Analysis of gene expression regulatory mechanisms.
- Evaluation of existing and potential drug targets and therapies.
Main Results:
- Nrf2 and BET proteins are established drug targets with ongoing clinical trials.
- The interaction between Nrf2 and BET proteins has significant implications for drug efficacy.
- This crosstalk is currently an overlooked factor in cancer and inflammatory disease treatments.
Conclusions:
- The regulatory interplay between Nrf2 and BET proteins is crucial in disease pathogenesis.
- Targeting Nrf2 or BET proteins individually has limitations.
- Combinatorial strategies targeting both Nrf2 and BET proteins may enhance therapeutic outcomes for cancer and inflammatory diseases.
More Related Videos
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
08:49Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
Published on: January 22, 2019
Related Concept Videos
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Activation and Inactivation of G Proteins
Endocrine Signaling
Yeast Signaling
Paracrine Signaling
Intracellular Signaling Cascades